Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | PLAT | P00750 | 1/20 | 0.37 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.37 |
| ▸ | HTR3B | O95264 | 2/20 | 0.37 |
| ▸ | HTR3A | P46098 | 2/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.37 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14486951 | 0.83 | LMNA (0.47) | LMNAKDM4EIDO1HTTF2 | |
| SCHEMBL4426660 | 0.80 | CES2 (0.56) | ALDH1A1IDO1F10TAS1R3TAS1R1 | |
| SCHEMBL8861494 | 0.80 | ALDH1A1 (0.54) | LMNAALDH1A1KDM4EGLAGAA | |
| SCHEMBL20054762 | 0.78 | ALDH1A1 (0.43) | ALDH1A1KDM4EGLAGAATP53 | |
| Hydrochloric Acid SCHEMBL1367092 | 0.78 | CES2 (0.54) | LMNAALDH1A1IDO1 | |
| SCHEMBL5742419 | 0.78 | CA1 (0.55) | LMNAALDH1A1IDO1HTTTP53 | |
| SCHEMBL2667939 | 0.78 | SMN1; SMN2 (0.50) | LMNAALDH1A1IDO1TP53HPGD | |
| SCHEMBL910922 | 0.78 | ALDH1A1 (0.56) | ALDH1A1KDM4EGLAGAATP53 | |
| SCHEMBL30564933 | 0.78 | ALDH1A1 (0.56) | ALDH1A1KDM4EGLAGAATP53 | |
| SCHEMBL18712125 | 0.78 | MEN1 (0.38) | ALDH1A1KDM4EGLAGAATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200171030-A1 | DUAL INHIBITORS OF ALK5 AND P38A MAP KINASE | INTEGRAL BIOSCIENCES PRIVATE LTD (IN) | 2020-06-04 | — | — | US | disclosed |
| WO-2019142128-A1 | DUAL INHIBITORS OF ALK5 AND P38Α MAP KINASE | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2019-07-25 | — | — | WO | disclosed |
| US-9987277-B2 | Carboxamide 4-[(4-pyridyl)amino] pryimidines for the treatment of hepatitis C | JANSSEN SCIENCES IRELAND UC (IE) | 2018-06-05 | — | — | US | disclosed |
| US-9987277-B2 | Carboxamide 4-[(4-pyridyl)amino] pryimidines for the treatment of hepatitis C | JANSSEN SCIENCES IRELAND UC (IE) | 2018-06-05 | — | — | US | disclosed |
| US-9987277-B2 | Carboxamide 4-[(4-pyridyl)amino] pryimidines for the treatment of hepatitis C | JANSSEN SCIENCES IRELAND UC (IE) | 2018-06-05 | — | — | US | disclosed |
| EP-2097084-B1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO] PYRIMIDINES FOR THE TREATMENT OF HEPATITIS C | JANSSEN R & D IRELAND (IE) | 2015-01-28 | — | — | EP | disclosed |
| EP-2097084-B1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO] PYRIMIDINES FOR THE TREATMENT OF HEPATITIS C | JANSSEN R & D IRELAND (IE) | 2015-01-28 | — | — | EP | disclosed |
| US-8030318-B2 | e.g. 4-[2-(5-Chloro-2-fluoro-phenyl)-7-(2-dimethylamino-ethylamino)-pyrido-[2,3-d]pyrimidin-4-ylamino]-nicotinic acid; viricide; transforming growth factor-beta inhibitor; hepatitis C infection; fibroproliferative conditions: fibrosis, glomerulonephritis, diabetic nephropathy, and certain cancers | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-10-04 | — | — | US | disclosed |
| US-8030318-B2 | e.g. 4-[2-(5-Chloro-2-fluoro-phenyl)-7-(2-dimethylamino-ethylamino)-pyrido-[2,3-d]pyrimidin-4-ylamino]-nicotinic acid; viricide; transforming growth factor-beta inhibitor; hepatitis C infection; fibroproliferative conditions: fibrosis, glomerulonephritis, diabetic nephropathy, and certain cancers | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-10-04 | — | — | US | disclosed |
| US-8030318-B2 | e.g. 4-[2-(5-Chloro-2-fluoro-phenyl)-7-(2-dimethylamino-ethylamino)-pyrido-[2,3-d]pyrimidin-4-ylamino]-nicotinic acid; viricide; transforming growth factor-beta inhibitor; hepatitis C infection; fibroproliferative conditions: fibrosis, glomerulonephritis, diabetic nephropathy, and certain cancers | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-10-04 | — | — | US | disclosed |
| WO-2006035061-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-04-06 | — | — | WO | disclosed |
| EP-1608631-A2 | BI-CYCLIC PYRIMIDINE INHIBITORS OF TGF BETA | SCIOS INC. (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050176957-A1 | Process for the preparation of pyridopyrimidones | SCIOS INC. | 2005-08-11 | — | — | US | disclosed |
| WO-2005065416-A2 | PROCESS FOR THE PREPARATION OF PYRIDOPYRIMIDONES | SCIOS INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| EP-1549316-A1 | INHIBITORS OF TFG&bgr; | SCIOS INC. (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20050004143-A1 | Bi-cyclic pyrimidine inhibitors of TGFbeta | SCIOS, INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2004087056-A2 | BI-CYCLIC PYRIMIDINE INHIBITORS OF TGFβ | SCIOS INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20040132730-A1 | Inhibitors of TGFbeta | SCIOS, INC. | 2004-07-08 | — | — | US | disclosed |
| WO-2004024159-A1 | INHIBITORS OF TFGβ | SCIOS INC. (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004024159-A1 | INHIBITORS OF TFGβ | SCIOS INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200171030-A1 | DUAL INHIBITORS OF ALK5 AND P38A MAP KINASE | MAP2K2, MAP2K5, MAP2K1 | LMNA 1589/4885ALDH1A1 646/4885KDM4E 1807/4885 |
| US-20050176957-A1 | Process for the preparation of pyridopyrimidones | PDXK, PNPO, AGPS | LMNA 838/4885ALDH1A1 1829/4885KDM4E 2063/4885 |
| US-20040132730-A1 | Inhibitors of TGFbeta | TGFBR1, TGFBR2, TGFB1 | LMNA 3045/4885ALDH1A1 2530/4885KDM4E 2670/4885 |
| US-20050004143-A1 | Bi-cyclic pyrimidine inhibitors of TGFbeta | TYMP, TYMS, TGFBR1 | LMNA 2007/4885ALDH1A1 2042/4885KDM4E 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.